EGCG was also proposed as an adjunct to anti-VEGFA therapy for wet AMD, based on its ability to down-regulate VEGFA expression, inhibit MAPK1/3 signaling, and protect retinal cells from oxidative damage [47]. This evidence concerns the gene VEGFA and wet macular degeneration.